This report describes and explains the induced pluripotent stem cell (iPSC) market and covers 2016-2021, termed the historic period, and 2021-2026 termed the forecast period, along with further forecasts for the period 2026-2031. The report evaluates the market across each region and for the major economies within each region.
The global induced pluripotent stem cell (iPSC) market reached a value of nearly $2,431.2 million in 2021, having increased at a compound annual growth rate (CAGR) of 10.8% since 2016. The market is expected to grow from $2,431.2 million in 2021 to $3,997.5 million in 2026 at a rate of 10.5%. The market is then expected to grow at a CAGR of 9.2% from 2026 and reach $6,195.8 million in 2031.
Growth in the historic period resulted from increased healthcare expenditure, a rise in funding, the development of non-animal alternatives for preclinical drug research, reduced cost for drug discovery and increasing demand for personalized medicine. Factors that negatively affected growth in the historic period were the lack of awareness on induced pluripotent stem cells and inadequate reimbursements.
Going forward, increasing prevalence of chronic diseases, growth in genomic projects, development of iPSC-derived disease models, increasing funding and increasing prevalence of genetic diseases will drive market growth. Factors that could hinder the growth of the induced pluripotent stem cell (iPSC) market in the future include automation of iPSC production, the risk associated with induced pluripotent stem cell treatment, high cost associated with storage, low per capita healthcare expenditure and disruption of medical facilities due to Russia-Ukraine war and the coronavirus pandemic.
The induced pluripotent stem cell (iPSC) market is segmented by derived cell type into hepatocytes, fibroblasts, keratinocytes, amniotic cells, and others. The fibroblasts was the largest segment of the induced pluripotent stem cell (iPSC) market by type, accounting for $728.0 million or 29.9% of the total market in 2021. The others market is expected to be the fastest-growing segment going forward at a CAGR of 12.3%.
The induced pluripotent stem cell (iPSC) market is segmented by application into academic research, drug discovery and toxicity studies, regenerative medicine and cell & gene therapy. The drug discovery and toxicity studies was the largest segment of the induced pluripotent stem cell (iPSC) market by application, accounting for $1,178.3 million or 48.5% of the total market in 2021. The cell & gene therapy market is expected to be the fastest-growing segment going forward at a CAGR of 12.0%.
The induced pluripotent stem cell (iPSC) market is segmented by end-users into hospitals, and research laboratories. The research laboratories market was the largest segment of the induced pluripotent stem cell (iPSC) market by end user, accounting for $1,658.7 million or 68.2% of the total market in 2021. The hospitals market is expected to be the fastest-growing segment going forward at a CAGR of 11.3%.
North America was the largest region in the induced pluripotent stem cell (iPSC) market, accounting for 48.9% of the global market in 2021. It was followed by Western Europe, Asia Pacific and the other regions. Going forward, the fastest growing regions in the induced pluripotent stem cell (iPSC) market will be South America and the Middle East, where growth will be at CAGRs of 35.1% and 33.5% respectively from 2021-2026.
The induced pluripotent stem cell (iPSC) market is highly fragmented, with a large number of players. The top ten competitors in the market made up to 27.50% of the total market in 2021. This is mainly due to the high growth potential of the market that is attracting the new players. FUJIFILM Holdings Corporation (FUJIFILM Cellular Dynamics, Inc) was the largest competitor with 10.46% share of the market, followed by Thermo Fisher Scientific, Inc with 6.43%, Takara Bio, Inc with 3.78%, Lonza Group AG with 2.81%, Astellas Pharma Inc with 1.51%, ViaCyte, Inc with 0.90%, Ncardia with 0.70%, REPROCELL USA, Inc with 0.62%, Japan Tissue Engineering Co., Ltd with 0.24%, and Merck KGaA with 0.05%.
The top opportunities in the induced pluripotent stem cell (iPSC) market by derived cell type will arise in the fibroblasts market, which will gain $456.5 million of global annual sales by 2026. The top opportunities in the induced pluripotent stem cell (iPSC) market by application will arise in the drug discovery & toxicity studies market, which will gain $710.9 million of global annual sales by 2026. The top opportunities in the induced pluripotent stem cell (iPSC) market by end-user will arise in the research laboratories market, which will gain $1,018.1 million of global annual sales by 2026. The induced pluripotent stem cell (iPSC) market size will gain the most in the USA at $253.7 million.
Market-trend-based strategies for the induced pluripotent stem cell (iPSC) market include investing in iPSC’s for treating Parkinson’s disease, focusing on strategic collaborations, investing in developing of iPSC-derived NK cells, focus on research and development, focus on investment in regenerative medicine, focus on advancements in technology transfer and clinical translation and focus on solutions for treating diabetes.
Player-adopted strategies in the induced pluripotent stem cell (iPSC) market include focus on expanding operational capabilities, focus on new product launches, focus on strategic agreements and focus on strategic collaborations and partnerships.
To take advantage of the opportunities, the publisher recommends the induced pluripotent stem cell (iPSC) companies to focus on pluripotent stem cells for treating Parkinson’s disease, focus on development of induced pluripotent stem cell (iPSC)-derived NK cells, focus on induced pluripotent stem cell (iPSC) for cell therapy, focus on use of pluripotent stem cells in treating type 1 diabetes, expand in emerging economies, continue to focus on developed markets, focus on strategic partnerships and collaborations, offer competitive prices, continue to use B2B promotions, continue to participate in events and conferences and target fast-growing applications.
The global induced pluripotent stem cell (iPSC) market reached a value of nearly $2,431.2 million in 2021, having increased at a compound annual growth rate (CAGR) of 10.8% since 2016. The market is expected to grow from $2,431.2 million in 2021 to $3,997.5 million in 2026 at a rate of 10.5%. The market is then expected to grow at a CAGR of 9.2% from 2026 and reach $6,195.8 million in 2031.
Growth in the historic period resulted from increased healthcare expenditure, a rise in funding, the development of non-animal alternatives for preclinical drug research, reduced cost for drug discovery and increasing demand for personalized medicine. Factors that negatively affected growth in the historic period were the lack of awareness on induced pluripotent stem cells and inadequate reimbursements.
Going forward, increasing prevalence of chronic diseases, growth in genomic projects, development of iPSC-derived disease models, increasing funding and increasing prevalence of genetic diseases will drive market growth. Factors that could hinder the growth of the induced pluripotent stem cell (iPSC) market in the future include automation of iPSC production, the risk associated with induced pluripotent stem cell treatment, high cost associated with storage, low per capita healthcare expenditure and disruption of medical facilities due to Russia-Ukraine war and the coronavirus pandemic.
The induced pluripotent stem cell (iPSC) market is segmented by derived cell type into hepatocytes, fibroblasts, keratinocytes, amniotic cells, and others. The fibroblasts was the largest segment of the induced pluripotent stem cell (iPSC) market by type, accounting for $728.0 million or 29.9% of the total market in 2021. The others market is expected to be the fastest-growing segment going forward at a CAGR of 12.3%.
The induced pluripotent stem cell (iPSC) market is segmented by application into academic research, drug discovery and toxicity studies, regenerative medicine and cell & gene therapy. The drug discovery and toxicity studies was the largest segment of the induced pluripotent stem cell (iPSC) market by application, accounting for $1,178.3 million or 48.5% of the total market in 2021. The cell & gene therapy market is expected to be the fastest-growing segment going forward at a CAGR of 12.0%.
The induced pluripotent stem cell (iPSC) market is segmented by end-users into hospitals, and research laboratories. The research laboratories market was the largest segment of the induced pluripotent stem cell (iPSC) market by end user, accounting for $1,658.7 million or 68.2% of the total market in 2021. The hospitals market is expected to be the fastest-growing segment going forward at a CAGR of 11.3%.
North America was the largest region in the induced pluripotent stem cell (iPSC) market, accounting for 48.9% of the global market in 2021. It was followed by Western Europe, Asia Pacific and the other regions. Going forward, the fastest growing regions in the induced pluripotent stem cell (iPSC) market will be South America and the Middle East, where growth will be at CAGRs of 35.1% and 33.5% respectively from 2021-2026.
The induced pluripotent stem cell (iPSC) market is highly fragmented, with a large number of players. The top ten competitors in the market made up to 27.50% of the total market in 2021. This is mainly due to the high growth potential of the market that is attracting the new players. FUJIFILM Holdings Corporation (FUJIFILM Cellular Dynamics, Inc) was the largest competitor with 10.46% share of the market, followed by Thermo Fisher Scientific, Inc with 6.43%, Takara Bio, Inc with 3.78%, Lonza Group AG with 2.81%, Astellas Pharma Inc with 1.51%, ViaCyte, Inc with 0.90%, Ncardia with 0.70%, REPROCELL USA, Inc with 0.62%, Japan Tissue Engineering Co., Ltd with 0.24%, and Merck KGaA with 0.05%.
The top opportunities in the induced pluripotent stem cell (iPSC) market by derived cell type will arise in the fibroblasts market, which will gain $456.5 million of global annual sales by 2026. The top opportunities in the induced pluripotent stem cell (iPSC) market by application will arise in the drug discovery & toxicity studies market, which will gain $710.9 million of global annual sales by 2026. The top opportunities in the induced pluripotent stem cell (iPSC) market by end-user will arise in the research laboratories market, which will gain $1,018.1 million of global annual sales by 2026. The induced pluripotent stem cell (iPSC) market size will gain the most in the USA at $253.7 million.
Market-trend-based strategies for the induced pluripotent stem cell (iPSC) market include investing in iPSC’s for treating Parkinson’s disease, focusing on strategic collaborations, investing in developing of iPSC-derived NK cells, focus on research and development, focus on investment in regenerative medicine, focus on advancements in technology transfer and clinical translation and focus on solutions for treating diabetes.
Player-adopted strategies in the induced pluripotent stem cell (iPSC) market include focus on expanding operational capabilities, focus on new product launches, focus on strategic agreements and focus on strategic collaborations and partnerships.
To take advantage of the opportunities, the publisher recommends the induced pluripotent stem cell (iPSC) companies to focus on pluripotent stem cells for treating Parkinson’s disease, focus on development of induced pluripotent stem cell (iPSC)-derived NK cells, focus on induced pluripotent stem cell (iPSC) for cell therapy, focus on use of pluripotent stem cells in treating type 1 diabetes, expand in emerging economies, continue to focus on developed markets, focus on strategic partnerships and collaborations, offer competitive prices, continue to use B2B promotions, continue to participate in events and conferences and target fast-growing applications.
Frequently Asked Questions about the Global Induced Pluripotent Stem Cell (iPSC) Market
What is the estimated value of the Global Induced Pluripotent Stem Cell (iPSC) Market?
What is the growth rate of the Global Induced Pluripotent Stem Cell (iPSC) Market?
What is the forecasted size of the Global Induced Pluripotent Stem Cell (iPSC) Market?
Who are the key companies in the Global Induced Pluripotent Stem Cell (iPSC) Market?
Report Attribute | Details |
---|---|
No. of Pages | 276 |
Published | November 2022 |
Forecast Period | 2021 - 2031 |
Estimated Market Value ( USD
| USD 2431.2 Million |
Forecasted Market Value ( USD
| USD 6195.8 Million |
Compound Annual Growth Rate | 9.8% |
Regions Covered | Global |
Table of Contents
1. Executive Summary2. Table of Contents3. List of Figures4. List of Tables5. Report Structure18. Competitive Landscape And Company Profiles
6. Introduction and Market Characteristics
7. Major Market Trends
8. Global Market Size And Growth
9. Global Market Segmentation
10. Global Market, Regional And Country Analysis
11. Asia-Pacific Market
12. Western Europe Market
13. Eastern Europe Market
14. North America Market
15. South America Market
16. Middle East Market
17. Africa Market
19. Company Profiles
20. Key Mergers and Acquisitions
21. Opportunities And Strategies
22. Biotechnology Services Market, Conclusions And Recommendations
23. Appendix
Executive Summary
Induced Pluripotent Stem Cell (IPSC) Global Market Opportunities And Strategies To 2031 from the publisher provides the strategists; marketers and senior management with the critical information they need to assess the global induced pluripotent stem cell (iPSC) market as it emerges from the COVID-19 shut down.Reasons to Purchase
- Gain a truly global perspective with the most comprehensive report available on this market covering 12 geographies
- Understand how the market is being affected by the coronavirus and how it is likely to emerge and grow as the impact of the virus abates
- Create regional and country strategies on the basis of local data and analysis
- Identify growth segments for investment
- Outperform competitors using forecast data and the drivers and trends shaping the market
- Understand customers based on the latest market research findings
- Benchmark performance against key competitors
- Utilize the relationships between key data sets for superior strategizing
- Suitable for supporting your internal and external presentations with reliable high-quality data and analysis
Description:
Where is the largest and fastest growing market for induced pluripotent stem cell (iPSC)? How does the market relate to the overall economy; demography and other similar markets? What forces will shape the market going forward? The induced pluripotent stem cell (iPSC) market global report from the publisher answers all these questions and many more.The report covers market characteristics; size and growth; segmentation; regional and country breakdowns; competitive landscape; market shares; trends and strategies for this market. It traces the market’s historic and forecast market growth by geography. It places the market within the context of the wider induced pluripotent stem cell (iPSC) market; and compares it with other markets.
The report covers the following chapters
- Introduction and Market Characteristics - Brief introduction to the segmentations covered in the market, definitions and explanations about the induced pluripotent stem cell (iPSC) market
- Key Trends - Highlights the major trends shaping the global induced pluripotent stem cell (iPSC) market. This section also highlights likely future developments in the market
- Global Market Size and Growth - Global historic (2016-2021) and forecast (2021-2026), and (2026-2031) market values, and drivers and restraints that support and control the growth of the market in the historic and forecast periods
- Regional And Country Analysis - Historic (2016-2021) and forecast (2021-2026), and (2026-2031) market values and growth and market share comparison by region and country
- Market Segmentation - Contains the market values (2016-2031) and analysis for for segment by derived cell type, by application, and by end-user in the market
- Regional Market Size and Growth - Regional market size (2021), historic (2016-2021) and forecast (2021-2026), and (2026-2031) market values, and growth and market share comparison of countries within the region. This report includes information on all the regions Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa and major countries within each region
- Competitive Landscape - Details on the competitive landscape of the market, estimated market shares and company profiles of the leading players
- Key Mergers and Acquisitions - Information on recent mergers and acquisitions in the market covered in the report. This section gives key financial details of mergers and acquisitions, which have shaped the market in recent years
- Market Opportunities And Strategies - Describes market opportunities and strategies based on findings of the research, with information on growth opportunities across countries, segments and strategies to be followed in those markets
- Conclusions And Recommendations - Includes recommendations for induced pluripotent stem cell (IPSC) providers in terms of product/service offerings, geographic expansion, marketing strategies and target groups
- Appendix
- This section includes details on the NAICS codes covered, abbreviations and currencies codes used in this report
Scope
Markets Covered:
- 1) By Derived Cell Type: Blood Cells; Hepatocytes; Fibroblasts; Keratinocytes; Amniotic Cells; Others
- 2) By Application: Academic Research; Drug Discovery And Toxicity Studies; Regenerative Medicine; Cell & Gene Therapy
- 3) By End-User: Hospitals; Research Laboratories
Countries: Australia; China; India; Indonesia; Japan; South Korea; USA; Brazil; France; Germany; UK; Russia
Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
Time series: Five years historic and ten years forecast.
Data: Ratios of market size and growth to related markets; GDP proportions; expenditure per capita; induced pluripotent stem cell (iPSC) indicators comparison.
Data segmentations: country and regional historic and forecast data; market share of competitors; market segments.
Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
Companies Mentioned
A selection of companies mentioned in this report includes:
- FUJIFILM Holdings Corporation (FUJIFILM Cellular Dynamics, Inc.)
- Thermo Fisher Scientific, Inc.
- Takara Bio, Inc.
- Lonza Group AG
- Astellas Pharma Inc.
Methodology
LOADING...